The global community acquired bacterial pneumonia (CABP) treatment market is projected to grow steadily over the next few years. The market is driven by increasing awareness about the disease and its treatment options, as well as advancements in technology that have made it easier to diagnose and treat the condition. The market for community acquired bacterial pneumonia (CABP) treatments is anticipated to reach a market size of US$ 5 billion in 2023 and US$ 8.38 billion by 2033, exhibiting a CAGR of 5.3%. From 2018 to 2022, the market for treating community-acquired bacterial pneumonia (CABP) experienced a CAGR of 3.2%.
One of the key drivers of the market is the rising incidence of CABP, particularly among the elderly population. As the global population ages, the incidence of CABP is expected to rise, which is likely to increase demand for CABP treatments. Additionally, the emergence of antibiotic-resistant strains of bacteria is likely to boost demand for novel therapies that can effectively treat these infections.
Empower your business with insights and knowledge from our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16837
The opportunities in the market include the development of new therapies and the growing demand for inhaled antibiotics. Inhaled antibiotics are a newer route of administration that is gaining popularity for the treatment of CABP. Inhaled antibiotics can deliver high concentrations of antibiotics directly to the lungs, which can be beneficial in treating infections that are resistant to systemic antibiotics. This is likely to drive demand for inhaled antibiotics in the coming years.
Geographically, North America is expected to dominate the CABP Treatment Market, followed by Europe and Asia Pacific. This can be attributed to the high prevalence of CABP in these regions, coupled with the availability of advanced healthcare infrastructure.
Key Takeaways from the Market Study:
- From 2018 to 2022, the Community Acquired Bacterial Pneumonia (CABP) Treatment market grew at a CAGR of 3.2%.
- The global Community Acquired Bacterial Pneumonia (CABP) Treatment market is expected to grow with a 5.3% CAGR during 2023 to 2033.
- As of 2033, the Community Acquired Bacterial Pneumonia (CABP) Treatment Market is expected to reach US$ 8.38 Billion.
- According to the FMI analysis, the hospital phamacies segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Community Acquired Bacterial Pneumonia (CABP) Treatment market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Community Acquired Bacterial Pneumonia (CABP) Treatment.” says an FMI analyst
Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-16837
Market Competition:
Key players in the market include companies such as Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix along with healthcare providers and technology companies among other global players.
- The U.S. Food and Drug Administration granted approval for Xenleta (lefamulin) to treat adults suffering from community-acquired bacterial pneumonia. This new drug provides an additional treatment option for patients with this serious illness, which can range in severity from mild to severe and affect people of all ages.
- According to the Centers for Disease Control and Prevention, about one million people in the United States are hospitalized with community-acquired pneumonia each year, and approximately 50,000 individuals succumb to the disease. Dr. Ed Cox, Director of FDA’s Office of Antimicrobial Products, stated that the approval of Xenleta is a significant step in facilitating the development of new antibiotics and addressing the treatment of infectious diseases.
Art of Personalization: Dive into the World of Customization with Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16837
Key Segments Profiled in the Community Acquired Bacterial Pneumonia (CABP) Treatment Industry Survey:
Dose Form:
- Solution
- Tablet
Drug Class:
- Pleuromutilin
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
Route of Administration:
- Oral
- Intravenous
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
